Managing Partner, Health Velocity Capital
Marty Felsenthal is a managing partner of Health Velocity Capital. He has worked exclusively with innovative, disruptive, and rapidly growing healthcare software and services companies for more than 20 years and has led investments in companies such as TelaDoc (NYSE: TDOC); Change Healthcare (acquired by Emdeon); MDLIVE (Cigna); OnShift (ShiftKey); Aperio (Leica Biosystems); Titan Health (United Surgical Partners); US Renal Care (Leonard Green); Payerpath (Misys/Allscripts); Vantage Oncology (McKesson); NovoLogix (CVS Health); VeriCare (MedOptions); IVX Health; Artera Health (fka Well Health); ClearData Networks; Array Behavioral Care; and Clever Care Health Plans. Marty was previously a partner at two leading venture and growth capital firms focused on this sector -- Salix Ventures and HLM Venture Partners - and also worked with Madison Dearborn Partners earlier in his career. He also serves as an adviser to the California Healthcare Foundation Innovation Fund. Marty received his AB from Princeton University and his MBA from the Stanford University Graduate School of Business.